Antipsychotics, mortality and schizophrenia: What are the facts?

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 262-263

  Tandon, Rajiv ^a   Nasrallah, Henry A ^b   Keshavan, Matcheri ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; LETTER; LIFESTYLE; MORTALITY; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 81955162896     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.08.020     Document Type: Letter

References (14)

1. Adams C.E., Coutinho E., Davis J.M., et al. Cochrane Schizophrenia Group publications. The Cochrane Library 2009, John Wiley and Sons, Chichester, United Kingdom, available at szg.cochrane.org, accessed July 19, 2011.
2. Buchanan R.W., Kreyenbuhl J., Kelly D.L., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
3. Dixon L.B., Dickerson F., Bellack A.S., et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:48-70.
4. Falkai P., Wobrock T., Lieberman J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2. Long-term treatment of schizophrenia. World J. Biol. Psychiatry 2006, 7:5-40.
5. Gilbert P., Harris M.J., McAdams L.A., et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch. Gen. Psychiatry. 1995, 52:173-188.
6. Gaebel W., Falkai P., Weinmann S., et al. Practice Guideline Schizophrenia, Vol 1: Practice Guidelines in Psychiatry and Psychotherapy of the German Society of Psychiatry, Psychotherapy, and Nervous Disease 2006, Steinkopff, Darmstadt, Germany.
7. Kane J.M., Leucht S., Carpenter D., et al. Expert consensus guideline series: optimizing pharmacological treatment of psychotic disorders. Introduction, methods, commentary, and summary. J. Clin Psychiatry 2003, 64(Suppl 12):5-19.
8. Leucht S., Barnes T.R.E., Kissling W., et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry. 2003, 160:1209-1222.
9. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry. 2007, 64:1123-1131.
10. Tandon R., Moller H.-J., Belmaker R.H., et al. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008, 100:20-38.
11. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
12. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 5. Treatment and prevention. Schizophr. Res. 2010, 122:1-23.
13. Tiihonen J., Lonnqvist J., Wahlbeck K., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
14. Weinemann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizoprenia: systematic review. Schizophr. Res. 2009, 113(1):1-11.